On this episode, we’ll hear about a combination therapy that improved progression-free survival in previously untreated patients with melanoma. Then, we’ll hear about a report that looked into the effects of prior radiotherapy on the development of adverse events in patients treated with immune checkpoint inhibitors.

Coverage of stories discussed this week on ascopost.com:

Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma

Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors

To listen to more podcasts from ASCO, visit asco.org/podcasts.